000186487 001__ 186487
000186487 005__ 20240229145748.0
000186487 0247_ $$2doi$$a10.3389/fonc.2022.1095947
000186487 0247_ $$2pmid$$apmid:36568249
000186487 0247_ $$2pmc$$apmc:PMC9775290
000186487 037__ $$aDKFZ-2022-03208
000186487 041__ $$aEnglish
000186487 082__ $$a610
000186487 1001_ $$aDu, Yijia$$b0
000186487 245__ $$aEditorial: Immunotherapy for NSCLC with oncogenic driver variants.
000186487 260__ $$aLausanne$$bFrontiers Media$$c2022
000186487 3367_ $$2DRIVER$$aarticle
000186487 3367_ $$2DataCite$$aOutput Types/Journal article
000186487 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1672316690_31235$$xEditorial
000186487 3367_ $$2BibTeX$$aARTICLE
000186487 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186487 3367_ $$00$$2EndNote$$aJournal Article
000186487 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000186487 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186487 650_7 $$2Other$$aimmune checkpoint inhibitors
000186487 650_7 $$2Other$$alung cancer
000186487 650_7 $$2Other$$aoncogenic driver variants
000186487 650_7 $$2Other$$atargeted therapy resistance
000186487 650_7 $$2Other$$atumor immune microenvironment
000186487 7001_ $$aChu, Qian$$b1
000186487 7001_ $$aLou, Yanyan$$b2
000186487 7001_ $$aHe, Yong$$b3
000186487 7001_ $$aHu, Hongbo$$b4
000186487 7001_ $$0P:(DE-He78)37890b29d23d511bbcc2a2fdf82ebe8d$$aHu, Qipeng$$b5$$udkfz
000186487 7001_ $$aHuang, Meijuan$$b6
000186487 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2022.1095947$$gVol. 12, p. 1095947$$p1095947$$tFrontiers in oncology$$v12$$x2234-943X$$y2022
000186487 909CO $$ooai:inrepo02.dkfz.de:186487$$pVDB
000186487 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)37890b29d23d511bbcc2a2fdf82ebe8d$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000186487 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000186487 9141_ $$y2022
000186487 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2021$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:25:45Z
000186487 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:25:45Z
000186487 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T13:25:45Z
000186487 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-11T13:25:45Z
000186487 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT ONCOL : 2021$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-08
000186487 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-08
000186487 9201_ $$0I:(DE-He78)F100-20160331$$kF100$$lF100 Pathologie infektionsbedingter Tumoren$$x0
000186487 980__ $$ajournal
000186487 980__ $$aVDB
000186487 980__ $$aI:(DE-He78)F100-20160331
000186487 980__ $$aUNRESTRICTED